Breast, Cervical, and Colorectal Cancer Screening Among New Jersey Medicaid Enrollees: 2017-2022.

Purpose: The COVID-19 pandemic disrupted cancer screenings in the United States, with disproportionate impact on health disparity populations. The objective of this study was to examine the impact of the pandemic on routine screening for breast, cervical, and colorectal cancer among Medicaid enrollees.

Materials and methods: This study is a retrospective, descriptive analysis to estimate the rate of breast, colorectal, and cervical cancer screenings among Medicaid enrollees age 50-75 years in New Jersey. Secondary enrollment and claims from the 2017-2022 Medicaid Management Information System were used. The results were stratified by screening type and socioeconomic factors. Bivariate analysis assessed between-group differences.

Results: Although April 2020 had the lowest screening rates in the 6-year period, rates for all three cancer types rebounded to prepandemic levels by late summer 2020. In 2022, breast cancer screening rates exceeded previous peaks. However, cervical and colorectal screening rates did not resume their prepandemic trajectories. Key findings comparing 2022 with 2019 were (1) across all three cancer screening groups, the younger group (50-64 years) had a higher screening rate than the older group (65-75 years); (2) Hispanic enrollees consistently had the highest screening rates; (3) the screening rate among dually eligible enrollees increased throughout the pandemic; and (4) there was wide screening variation by geographic region.

Conclusion: Multilevel, multisectoral approaches, including policy and health system strategies, are critical to addressing gaps in care for Medicaid enrollees. Future efforts should focus on bolstering cervical and colorectal cancer screening rates and ensuring equitable access to cancer screening and treatment.